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Prostate cancerAbstract Background: Cixutumumab, a human monoclonal antibody (HuMAb), targets the
insulin-like growth factor receptor. Ramucirumab is a recombinant HuMAb that binds to vas-
cular endothelial growth factor receptor-2. A non-comparative randomised phase II study
evaluated cixutumumab or ramucirumab plus mitoxantrone and prednisone (MP) in
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received mitoxantrone 12 mg/m2 on day 1 and prednisone 5 mg twice daily and were random-
ised 1:1 to receive either cixutumumab or ramucirumab 6 mg/kg intravenously weekly in a
21-day cycle. Primary end-point was composite progression-free survival (cPFS). Secondary
end-points included safety, response, radiographic progression-free survival (PFS) and overall
survival (OS). Sample size was based on a 50% increase in median cPFS from 2.6 (MP) to
3.9 months (either combination).
Results: 132 men were treated (66 per arm). Median cPFS was 4.1 months (95% conﬁdence
interval (CI), 2.2–5.6) for cixutumumab and 6.7 months (95% CI, 4.5–8.3) for ramucirumab.
Median time to radiographic progression was 7.5 months for cixutumumab and 10.2 months
for ramucirumab, with a median OS of 10.8 and 13.0 months, respectively. Fatigue was the
most frequent adverse event (AE). Incidence of most non-haematologic grade 3–4 AEs was
<10% on both arms. Grade 3 cardiac dysfunction occurred in 7.6% of patients on ramuciru-
mab.
Conclusion: Combinations of cixutumumab or ramucirumab plus MP were feasible and asso-
ciated with moderate toxicities in docetaxel-pretreated men with mCRPC. Of the two regi-
mens, the ramucirumab regimen is worthy of further testing based on the observed cPFS
relative to the historical control.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite signiﬁcant progress in therapy development
for patients with metastatic castration-resistant prostate
cancer (mCRPC), survival is limited and better treat-
ments are needed [1–3]. Insulin-like growth factor
(IGF) and type-1 receptor (IGF-IR)-mediated signalling
can potentiate androgen-receptor activation [4], and
IGF-IR signalling contributes to proliferation,
tumour-stromal interactions, invasion and metastasis
[5–9] in preclinical models of prostate cancer (PC).
Anti–IGF-IR antibodies, IGF-IR kinase inhibitors and
antisense oligonucleotides to IGF-IR inhibit PC growth
in vitro and in vivo [10–12].
Cixutumumab (IMC-A12) is a human immunoglobu-
lin G, subclass 1 (IgG1) monoclonal antibody (MAb)
with high aﬃnity and speciﬁcity for IGF-IR and is an
antagonist of IGF-I and IGF-II ligand binding and sig-
nalling [13,14]. Cixutumumab inhibits the proliferation
and growth of a variety of human tumour cell lines, both
in vitro and in vivo [13]. Cixutumumab inhibited growth
of androgen-dependent and androgen-independent
xenograft prostate tumours and growth inhibition was
enhanced when cixutumumab was co-administered with
docetaxel in CRPC models [14,15]. Preclinical data sug-
gest that cixutumumab monotherapy inhibits but does
not completely arrest tumour growth, with the most
profound eﬀects observed when IGF-IR inhibitors are
combined with other agents [16]. In a phase II study
of cixutumumab monotherapy in mCRPC patients, 9
of 31 (29%) had disease stabilisation for at least
6 months and cixutumumab was found to be well toler-
ated [17].
Vascular endothelial growth factor (VEGF) is
up-regulated in PC, and higher expression has beenassociated with higher grade [18], more advanced dis-
ease, rapid progression and shorter survival [19–22].
Microvessel density and VEGF expression are
increased in PC and higher levels of circulating and
tumour VEGF are associated with aggressive clinical
and preclinical PC phenotypes [18,20–22]. Inhibition
of VEGF receptor-2 (VEGFR-2) with the antibody
DC101 inhibits PC growth and bone metastasis in
murine models [23]. Ramucirumab is a recombinant
human IgG1 MAb that binds speciﬁcally and with
high aﬃnity to VEGFR-2, and inhibits receptor acti-
vation [24]. Preclinical cellular and animal models of
solid and liquid tumours have demonstrated that
ramucirumab attacks its intended target with inhibi-
tion of VEGF-induced VEGFR-2 activation and inhi-
bition of VEGF-stimulated cellular migration and
proliferation, and eﬃcacy has been demonstrated in
phase I trials, particularly in heavily pretreated refrac-
tory patients [25].
At the time of the study design, mCRPC patients pro-
gressing on docetaxel had no life-prolonging therapy
choices and the only available treatment was the combi-
nation of mitoxantrone and prednisone, which was
approved for pain palliation [26].
Based on the biological and preclinical data, we
hypothesised that cixutumumab or ramucirumab
would enhance the activity of mitoxantrone and pred-
nisone in men with docetaxel-pretreated mCRPC. The
study was designed and completed before the regula-
tory approvals of cabazitaxel, abiraterone, enzaluta-
mide and radium-223 in the post-docetaxel setting.
Thus, we conducted a randomised, open-label,
non-comparative phase II study of cixutumumab or
ramucirumab plus mitoxantrone and prednisone in
patients with mCRPC.
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2.1. Eligibility criteria
Eligible patients were men P18 years old with histo-
logically conﬁrmed prostate adenocarcinoma,
castration-resistant disease, radiographic evidence of
metastases, an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0–2 and
prostate-speciﬁc antigen (PSA) P2 ng/mL. Patients
had disease progression during or within 120 days of
completion of or documented intolerance of docetaxel.
Disease progression was deﬁned as at least one of the
following: (1) progressive measurable disease using
Response Evaluation Criteria in Solid Tumors
(RECIST 1.0), (2) bone scan progression, with at least
two new lesions, and/or (3) increasing PSA, with at least
two consecutive rising PSA values over a reference value
taken at least 1 week apart. Patients were required to
have surgical or medical castration with a serum testos-
terone level <50 ng/mL. Non-surgically castrated
patients continued using luteinizing hormone releasing
hormone agonists during study treatment.
Patients were excluded for prior therapy with
mitoxantrone, radionuclide therapy with ongoing evi-
dence of bone marrow dysfunction or inadequate symp-
tom control or left ventricular ejection fraction (LVEF)
that was P10% below the lower limit of normal (multi-
gated acquisition scan [MUGA]).
The study was undertaken in accordance with princi-
ples of the Declaration of Helsinki and Good Clinical
Practice guidelines, and with local ethics committee
approval. Written informed consent was obtained from
all participants.2.2. Randomisation, treatment and disease monitoring
Randomisation was stratiﬁed by ECOG PS of 2 (ver-
sus 0 or 1), the presence (versus absence) of PC-related
bone pain requiring frequent opiate analgesic therapy
(deﬁned as use P50% of days during the week before
randomisation) and stable disease (SD) or better (com-
plete response [CR], partial response [PR]) as best
response to prior docetaxel therapy versus progressive
disease (Supplemental Table A.1).
Patients were randomised 1:1 to open-label cixutu-
mumab 6 mg/kg or ramucirumab 6 mg/kg intravenously
over 1 h on days 1, 8 and 15 of 3-week (21-day) cycles.
Patients received oral prednisone 5 mg twice daily and
mitoxantrone 12 mg/m2 intravenously on day 1 every
21 days for a maximum of 12 cycles. Treatment contin-
ued until disease progression, death, intolerable toxicity
or other withdrawal criteria were met. Experimental
drug was continued if mitoxantrone was stopped.
Patients were followed until the cutoﬀ date for analysis
or until death.Baseline evaluations included medical history, physi-
cal examination, biochemistry, haematology, PSA and
electrocardiogram. Patients were monitored throughout
the study for PS, adverse event (AE) assessment, record-
ing of concomitant medications and echocardiogram or
MUGA to assess LVEF. AEs were collected weekly and
graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events
(NCI-CTCAE), version 3.0. Computerised tomography
scan or magnetic resonance imaging of abdomen, pelvis
and bone scans were repeated after the initial 9 weeks of
therapy and thereafter every 6 weeks.
The primary end-point of composite progression-free
survival (cPFS) was deﬁned as time from randomisation
to any of the following: (1) tumour progression by
RECIST 1.0; (2) at least two new lesions detected on
bone scan [27]; (3) new skeletal events (pathologic bone
fracture in an area of metastatic disease, bone lesions
requiring radiation therapy or surgery or spinal cord
or nerve root compression); (4) symptomatic progres-
sion, deﬁned as a deterioration in ECOG PS of two or
more points or weight loss of 20% or more from base-
line; (5) other prostate cancer-related clinical events
requiring major interventions, or; (6) death.2.3. Biomarker analyses
Biomarkers were measured as exploratory analyses
(Intertek Alta Analytical Laboratory, San Diego, CA).
A total of 23 analytes were measured using non-GLP
quantitative sandwich electrochemiluminescence proto-
type kits. Analytes assayed, in all treated patients from
whom samples were provided and who signed the
appropriate consent, included: VEGF (VEGF-A),
VEGF-C, VEGF-D, placental growth factor (PlGF),
soluble VEGFR-1 (sFlt-1), soluble VEGFR-2 (KDR),
angiopoietin-1, angiopoietin-2, HGF, SDF-1A,
bFGF/FGF2, thrombomodulin, E-Selectin, P-Selectin,
SAA, CRP, VCAM-1, ICAM-1, ICAM-3, IL-12, IL-4,
IL-8 and C-KIT.2.4. Statistical analyses
This randomised non-comparative trial was designed
to evaluate two promising regimens in a comparable
population to select the best combination for potential
future phase III testing. Considering available data
regarding cPFS associated with minimally eﬀective che-
motherapy in a randomised phase III trial at the time of
study design [28], and to increase the eﬃciency of con-
ducting this trial, the study was designed without a
mitoxantrone–prednisone control arm. A sample size
of 66 patients per arm (132 patients in total) was
required to detect an increase of 50% in median cPFS
to 3.9 months with either combination as compared with
2.6 months cPFS with mitoxantrone–prednisone in
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at a 0.025 signiﬁcance level, assuming a 52-week accrual
period and total study duration of 104 weeks. The arms
were analysed separately using SAS, version 8.2 or
higher (SAS Institute, Cary, NC). The PSA response
rate was calculated based on the proportion of patients
with a decrease in PSAP 50% from baseline.
Composite progression-free survival (cPFS) and overall
survival (OS) were analysed using the Kaplan–Meier
method. Cox regression was used to assess correlations
between the time-to-event outcomes and biomarkers at
baseline (additional details in Data Supplement).3. Results
3.1. Patient characteristics
Between August 2008 and September 2011, 132
mCRPC patients (66 per arm) were randomised and trea-
ted at 35 centres across theUnited States (Fig. 1). Baseline
demographics and disease-related characteristics were
similar for both arms (Table 1). ApproximatelyAssessed for eligi
(N=165) Enrollment 
Lost to follow-up (n=0)
Discontinued intervention (n=66) 
• Adverse event (14) 
• Progressive disease (44) 
• Protocol violation (0) 
• Withdrawal by subject (4) 
• Other (4) 
Allocated to CIX (n=69)
 Received CIX (n=66) 
 Did not receive CIX (n=3) 
• Intractable pain 
• Spinal cord compression 




Excluded from analysis (n=0)
Allocat
Analys
Fig. 1. CONSORT diagram. Abbreviations: Cone-third of the study population had metastases to liver,
lung, peritoneum, pleura or adrenal gland, with or with-
out involvement of other sites (43.9% cixutumumab;
33.3% ramucirumab).3.2. Treatment summary
Most patients on both arms (62 [93.9%] and 65
[98.5%]) received two or more doses of cixutumumab
or ramucirumab, respectively. Median duration of ther-
apy was 15.0 weeks (range, 1.0–117.1) on cixutumumab
and 19.0 weeks (range, 1.0–86.0) on ramucirumab. Most
patients (89.4% cixutumumab; 87.9% ramucirumab) had
no dose reductions. Discontinuations due to AEs
occurred in 14/69 (20.3%) patients on cixutumumab
and 26/69 (37.7%) patients on ramucirumab (Fig. 1).
Administration and exposure of cixutumumab, ramuci-
rumab and mitoxantrone are provided in Supplemental
Table A.2.
Approximately half of the patients (cixutumumab
59.1%; ramucirumab 50.0%) received additional
post-study therapy. The most frequent types ofbility
Excluded (n=27)
 Did not meet inclusion criteria (25) 
 Declined to participate (1) 
 Adverse event (1)  
Allocated to RAM (n=69)
 Received RAM (n=66) 
 Did not receive RAM (n=3) 
• Supraventricular arrhythmia 
• Dizziness 
• Recurrent cellulitis in the left neck 
Analysed (n=66)
Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=66) 
• Adverse event (26) 
• Progressive disease (34) 
• Protocol violation (1) 
• Withdrawal by subject (2) 




IX, cixutumumab; RAM, ramucirumab.
Table 1
Baseline patient demographics and clinical characteristics.
Cixutumumab +M + P (n = 66) Ramucirumab +M + P (n = 66)
Age, years
Median (range) 65 (48–88) 68 (46–86)
18 to <65 30 (45.5) 21 (31.8)
P65 36 (54.5) 45 (68.2)
Race, n (%)
Black or African American 4 (6.1) 6 (9.1)
White 61 (92.4) 58 (87.9)
Other 1 (1.5) 2 (3.0)
Ethnic origin, n (%)
Hispanic or latino 1 (1.5) 3 (4.5)
Not hispanic or latino 65 (98.5) 63 (95.5)
ECOG PS, n (%)
0 23 (34.8) 19 (28.8)
1 38 (57.6) 41 (62.1)
2 5 (7.6) 6 (9.1)
Disease site, n (%)
Bone only 13 (19.7) 18 (27.3)
Lymph nodes with/without bones 17 (25.8) 19 (28.8)
Viscera 29 (43.9) 22 (33.3)
Skin/soft tissue with/without others 7 (10.6) 7 (10.6)
Prior docetaxel therapy, n (%)
1 regimen 56 (84.8) 54 (81.8)
2 regimens 9 (13.6) 11 (16.7)
3 regimens 1 (1.5) 1 (1.5)
PD on prior docetaxel, n (%)
During therapy 38 (57.6) 41 (62.1)
Within 3 m of last dose 13 (19.7) 9 (13.6)
>3 m of last dose 6 (9.1) 9 (13.6)
Not complete/available 9 (13.6) 7 (10.6)
Pain during week prior to randomisation, n (%)
Required opiate P50% of days 28 (42.4) 33 (50.0)
Did not require opiate P50% of days 38 (57.6) 33 (50.0)
Stratiﬁcation, n (%)
PS = 2 or opiate P50% of days 31 (47.0) 35 (53.0)
PS 0–1 and opiate <50% of days 35 (53.0) 31 (47.0)
Stratiﬁcation (best response prior therapy), n (%)
CR, PR, SD on docetaxel 29 (43.9) 27 (40.9)
PD on or intolerant to docetaxel 37 (56.1) 39 (59.1)
PSA, lg/mL
Median, range 133.45 (0.1–5530.0) 107.30 (2.2–5826.4)
Duration of disease (from diagnosis to ﬁrst dose), m
Mean, (standard deviation) 65.9 (50.6) 71.2 (56.2)
Abbreviations: CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; m, months; M, mitoxantrone; P,
prednisone; PD, progressive disease; PR, partial response; SD, stable disease; PSA, prostate-speciﬁc antigen.
1718 M. Hussain et al. / European Journal of Cancer 51 (2015) 1714–1724post-study therapy received were chemotherapy (42.4%
and 36.4%) and radiotherapy (24.2% and 15.2%)
(Supplemental Table A.3).
3.3. Eﬃcacy
The median cPFS was 4.1 months (95% conﬁdence
interval (CI), 2.2–5.6) for cixutumumab and 6.7 months
(95% CI, 4.5–8.3) for ramucirumab (Fig. 2a). The
6-month cPFS rates were 37.2% for cixutumumab and59.2% for ramucirumab (Table 2). Median time to
radiographic disease progression (RECIST or bone scan
criteria) was 7.5 months (95% CI, 4.8–10.1) on cixutu-
mumab and 10.2 months (95% CI, 7.5–12.6) on ramuci-
rumab (Fig. 2b). Median OS was 10.8 months (95% CI,
6.5–13.0) on cixutumumab and 13.0 months (95% CI,
9.5–16.0) on ramucirumab (Fig. 2c). A PSA decline of
P50% from baseline occurred in 18.5% of patients on
cixutumumab and 21.4% of patients on ramucirumab
(Fig. 3). In the subset of patients with measurable
Composite Progression-free Survival (Months)





































Cixutumumab* 66 41 29 21 11 9 6 5 3 2 2 1
Ramucirumab* 66 58 37 32 19 14 8 5 2 2 1 0
Cixutumumab* = Cixutumumab + Mitoxantrone + Prednisone
Ramucirumab* = Ramucirumab + Mitoxantrone + Prednisone
Cixutumumab* Ramucirumab*
Median 4.1 months 6.7 months
Fig. 2a. Kaplan–Meier analysis of time to composite progression-free survival.
Radiographic Progression-free Survival (Months)












































Median 7.5 months 10.2 months
At Risk
Cixutumumab* 66 40 29 22 13 9 6 5 3 2 2 1
Ramucirumab* 66 56 37 32 22 15 9 6 3 2 1 0
Cixutumumab* = Cixutumumab + Mitoxantrone + Prednisone
Ramucirumab* = Ramucirumab + Mitoxantrone + Prednisone
Fig. 2b. Kaplan–Meier analysis of time to radiographic evident disease progression.
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(7/46) (cixutumumab) and 31.6% (12/38) (ramucirumab)
(Table 2). The disease control rate (DCR, deﬁned as
CR + PR + SD) for all patients was 65.2% (cixutumu-
mab: 95% CI, 52.4–76.5) and 77.3% (ramucirumab:
95% CI, 65.3–86.7) (Table 2).3.4. Safety
Regardless of causality, fatigue (any grade) was the
most frequent AE (Table 3), and the incidence of most
non-haematologic grade 3–4 AEs was <10% on both
arms. The incidence of hyperglycaemia and dehydration
Overall Survival (Months)


























Median 10.8 months 13.0 months
At Risk
Cixutumumab* 66 57 50 43 36 35 27 23 22 18 16 13 11 6 5 3 1 0 0
Ramucircumab* 66 63 58 53 49 39 35 30 24 18 16 14 13 6 3 3 2 2 1
Cixutumumab* = Cixutumumab + Mitoxantrone + Prednisone
Ramucircumab* = Ramucirumab + Mitoxantrone + Prednisone
Fig. 2c. Kaplan–Meier analysis of overall survival.
Table 2
Eﬃcacy results.
Cixutumumab +M + P Ramucirumab +M + P
Composite progression-free survival (n = 66) (n = 66)
Median, months 4.1 6.7
95% CI 2.2–5.6 4.5–8.3
Rate at 6 months, % 37.2 59.2
95% CI 25.0–49.4 45.8–70.4
Rate at 12 months, % 12.4 20.0
95% CI 5.2–22.9 10.1–32.3
Overall survival (n = 66) (n = 66)
Median, months 10.8 13.0
95% CI 6.5–13.0 9.5–16.0
Rate at 6 months, % 66.3 80.3
95% CI 53.5–76.4 68.5–88.1
Rate at 12 months, % 41.6 54.2
95% CI 29.6–53.2 41.4–65.3
PSA response (n = 54) (n = 56)
P50% decline from baseline, % 18.5 21.4
95% CIa 9.3–31.4 11.6–34.4
Objective response (CR + PR)
Measurable disease (n = 46) (n = 38)
Response rate, % 15.2 31.6
95% CIa 6.3–28.9 17.5–48.7
Disease control rate (CR + PR + SD) (n = 66) (n = 66)
Response rate, % 65.2 77.3
95% CIa 52.4–76.5 65.3–86.7
Duration of follow-upb
Median, months 28.6 26.9
Abbreviations: CI, conﬁdence interval; CR, complete response; M, mitoxantrone; P, prednisone; PR, partial response; PSA, prostate-speciﬁc
antigen; SD, stable disease.
a Binomial exact conﬁdence interval.
b Duration of follow-up calculation was made using the Kaplan–Meier method of analysis.
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Fig. 3. Waterfall plot for best percent change in prostate-speciﬁc antigen (PSA) from baseline. Response deﬁned as P50% PSA decrease from
baseline and progression deﬁned as 25% PSA increase. Abbreviations: CIX, cixutumumab; M, mitoxantrone; P, prednisone; RAM, ramucirumab.
*Truncated at 200%.
Table 3
Most frequent treatment-emergent non-haematologic and haematologic adverse events (P20% any grade on either arm).a
Cixutumumab +M + P (n = 66) Ramucirumab + M + P (n = 66)
Any G, % G3, % G4, % Any G, % G3, % G4, %
Non-haematologic AE
Fatigue 74.2 16.7 0 71.2 7.6 0
Weight decreased 65.2 4.5 0 60.6 1.5 0
Anorexia 53.0 0 0 47.0 3.0 0
Nausea 53.0 1.5 0 47.0 4.5 0
Diarrhoea 43.9 7.6 0 45.5 1.5 0
Constipation 40.9 0 0 37.9 1.5 0
Hyperglycaemia 47.0 7.6 1.5 12.1 1.5 1.5
Vomiting 28.8 1.5 0 28.8 3.0 0
Dehydration 28.8 6.1 0 7.6 1.5 0
Arthralgia 25.8 6.1 0 24.2 4.5 0
Back pain 24.2 4.5 0 24.2 1.5 0
Dyspnoea 18.2 3.0 0 31.8 7.6 0
Peripheral oedema 15.2 1.5 0 21.2 0 0
Ecchymosis 15.2 0 0 24.2 0 0
Stomatitis 10.6 0 0 22.7 0 0
Hypertension 7.6 1.5 0 34.8 9.1 0
Haematologic AE
Neutropenia 42.4 16.7 15.2 37.9 22.7 9.1b
Anaemia 34.8 3.0 0 36.4 10.6 0
Leucopaenia 31.8 16.7 6.1 25.8 15.2 1.5
Thrombocytopenia 18.2 3.0 1.5 34.8 7.6 0
Abbreviations: AE, adverse event; G, grade; M, mitoxantrone; P, prednisone.
a Deaths assessed to be related to study treatment: ramucirumab arm, septic shock and pneumonia aspiration; cixutumumab arm, cachexia.
b Includes 1 incidence (1.5%) of grade 5 neutropenia on ramucirumab.
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mab, respectively. Hypertension (34.8%), thrombocyto-
penia (34.8%), and dyspnoea (31.8%) were seen in
>20% of patients on ramucirumab. Treatment-related
serious AEs occurred in 22 patients (33.3%) on cixutu-
mumab and 16 patients (24.2%) on ramucirumab.
At the time of analysis, 57 patients (86.4%) had died
in the cixutumumab arm and 54 patients (81.8%) in the
ramucirumab arm; 10 patients (15.2%) and 6 patients
(9.1%) died while either on study or within 30 days oflast dose of study drug in the cixutumumab and ramuci-
rumab arms, respectively. Four deaths on each arm were
attributed to AEs, three of which were considered
related to study treatment (one on cixutumumab arm
and two on ramucirumab) (Table 3).
Cardiac dysfunction occurred in 16 patients (24.2%; 5
[7.6%] with grade 3) and 9 patients (13.6%; no grade 3
events reported) on ramucirumab and cixutumumab,
respectively (Supplemental Table A.4). No grade 4–5
cardiac dysfunction was observed in either study arm.
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line was 6.0 months (range, 2.1–16.1) for cixutumumab
and 5.1 months (range, 1.9–9.0) for ramucirumab. In
patients who experienced cardiac dysfunction as an
AE, the median time to event was 5.6 months (range,
2.1–16.1) on cixutumumab and 5.0 months (range, 2.0–
7.9) on ramucirumab.3.5. Biomarkers
For the majority of biomarkers assessed, there were
no signiﬁcant associations between baseline levels and
cPFS or OS (data not shown). However, a potential
association between higher baseline levels of IL-8 and
both shorter cPFS and OS was identiﬁed
(Supplemental Table A.5) for patients on both arms.
The treatment beneﬁt, as estimated by the model, of
ramucirumab over cixutumumab is greater for patients
with higher baseline levels of IL-8. However, these rela-
tionships were not consistent across end-points and
models. These results have not been adjusted for statis-
tical testing of multiple hypotheses, and hence should
only be considered as hypothesis-generating. Increases
in pharmacodynamic markers PlGF and VEGF-A were
observed following ramucirumab but not cixutumumab
administration (data not shown).4. Discussion
In this randomised, non-comparative phase II study,
the combination of cixutumumab or ramucirumab with
mitoxantrone–prednisone resulted in moderate disease
control. The median cPFS of 4.1 months for the cixutu-
mumab arm marginally exceeded the projected median
target of 3.9 months used to estimate sample size,
whereas the median cPFS for the ramucirumab arm of
6.7 months exceeded the projected median.
The benchmark for cPFS (median of 2.6 months) was
based on contemporary data available for mitoxan-
trone–prednisone following docetaxel at the time of
the study design (SPARC phase III study in mCRPC).
Although the cPFS of both combinations exceeded that
observed in SPARC [29], disease control and survival
appeared longer on the ramucirumab arm.
During the conduct of this study, results from a ran-
domised phase III study evaluating cabazitaxel versus
mitoxantrone–prednisone in a post-docetaxel setting
(TROPIC) were published. A median OS for mitoxan-
trone–prednisone of 12.7 months was reported [30],
which is comparable to that observed for ramucirumab
plus mitoxantrone–prednisone in the current study
(13.0 months), although cross-study comparisons are
inherently diﬃcult.
The AEs reported for cixutumumab and ramuciru-
mab in combination with mitoxantrone–prednisone
were generally consistent with known safety proﬁles ofcixutumumab or ramucirumab and mitoxantrone. A
higher incidence of cardiac dysfunction (including grade
3) was observed with ramucirumab plus mitoxantrone–
prednisone. It is likely that ramucirumab enhances the
cardiotoxicity associated with mitoxantrone. Future
studies of this agent should consider combinations that
have a higher beneﬁt-to-risk potential.
In an exploratory biomarker analysis, evidence of a
potential association was observed between IL-8 levels
and eﬃcacy outcomes. This association appears to be
primarily prognostic, with higher IL-8 levels associated
with worse clinical outcome for both arms.
Limitations of the current study include absence of a
chemotherapy control arm and availability of improved
treatment options in mCRPC since study inception,
including several eﬃcacious systemic agents rendering
mitoxantrone’s use in this disease less certain.
Although progress in mCRPC therapy has recently
occurred, improvements in OS remain modest and
newer agents and rational combinations targeting bio-
logically relevant pathways remain important.
Several anti-angiogenic therapies have failed to
impact survival in patients with mCRPC. Whether this
is a function of the agent/target, disease setting or bio-
logical context remains to be determined. In
early-phase clinical trials of cixutumumab, targeting
IGF-IR in patients with mCRPC has demonstrated
both biologic and clinical activity [17]. However, the
addition of cixutumumab to androgen-deprivation ther-
apy failed to meet the primary end-point of undetectable
PSA response (ie, 60.2 ng/mL) compared with
androgen-deprivation therapy [31]. The totality of the
biological data does indicate the importance of angio-
genesis in mCRPC, thus targeting other elements of
the angiogenic pathway may be relevant. In phase III
trials, ramucirumab has demonstrated improved OS in
patients with resistant gastric cancer [32,33], metastatic
colorectal carcinoma [34] and metastatic lung cancer
[35]. A recent randomised phase II study of docetaxel
with or without ramucirumab demonstrated a signiﬁ-
cant improvement in PFS for docetaxel plus ramuciru-
mab in second-line metastatic urothelial carcinoma
[36]. These data coupled with the observation from this
study provide the rationale for further evaluation of
ramucirumab in mCRPC. This should be informed by
preclinical evaluation in CRPC models resistant to enza-
lutamide and abiraterone to better elucidate the poten-
tial use of ramucirumab in the current clinical context.Conﬂict of interest statement
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